Darren Shafren
Oprichter bij ImmVirX Pty Ltd.
Profiel
Darren Shafren is the founder of ImmVirX Pty Ltd.
He is currently an Associate Professor at The University of Newcastle.
Previously, he served as the Chief Scientific Officer at Viralytics Pty Ltd.
from 2009 to 2019.
Actieve functies van Darren Shafren
| Bedrijven | Functie | Begin |
|---|---|---|
| The University of Newcastle | Corporate Officer/Principal | - |
ImmVirX Pty Ltd.
 ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Oprichter | - |
Eerdere bekende functies van Darren Shafren
| Bedrijven | Functie | Einde |
|---|---|---|
| VIRALYTICS LTD. | Directeur van Onderzoek - Eigen Vermogen | 25-10-2009 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |